Search
for
Sort by
Research 301–330 of 554
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
- CO149 Does the EQ-5D Measure the Full Impact of Alopecia Areata on Patients' Health Related Quality of Life?
- Survey of pediatric dermatologist views on treatment for alopecia areata
- Most men choose eyebrows versus scalp hair: Response to Mostaghimi et al., “Evaluation of eyebrow and eyelash regrowth and patient satisfaction in the phase 3 THRIVE-AA2 trial of deuruxolitinib in adult patients with alopecia areata”
- Relapse of alopecia areata during ongoing Janus kinase inhibitor therapy is not uncommon and usually occurs in previously affected areas: A multicenter Italian real-world study
- A Pilot Randomized Controlled Trial Comparing the Efficacy and Safety of Oral Tofacitinib Versus Methotrexate In Moderate-to-Severe Alopecia Areata
- Clinical Trial Eligibility in Real‐World Alopecia Areata Patients Treated With Baricitinib
- Nitric oxide-releasing nanocarriers integrated with ginsenoside compound K in dissolvable microneedles for androgenetic alopecia
- Abrocitinib in the Treatment of Severe Alopecia Areata in a Pediatric Patient: A Case Report
- Oral Tofacitinib in Refractory Pediatric Alopecia Areata
- Successful treatment of severe diffuse alopecia areata with abrocitinib
- Baricitinib Effectiveness in JAKi‐Naïve and Tofacitinib‐Exposed Patients: A Prospective Study in Alopecia Areata
- Alopecia universalis with IL-12-RB1 and STAT4 mutations effectively treated with upadacitinib
- Determining meaningful thresholds for evaluating treatment efficacy in patients with alopecia areata
- Characteristics and Outcomes of Patients on Tofacitinib for Alopecia Areata or Rheumatoid Arthritis: A Retrospective Cohort Study
- Treatment preferences of adults and adolescents with alopecia areata: A discrete choice experiment
- Upadacitinib for the treatment of alopecia areata – A case report
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Alopecia Areata: Current Treatments and New Directions
- Effect of different types of therapeutic trauma on vitiligo lesions
- A review of Janus kinase inhibitor use in scarring alopecia
- A retrospective analysis of disease epidemiology, comorbidities, treatment patterns, and healthcare resource utilization of alopecia areata in the United Arab Emirates using claims database
- Recent Insights in Multi‐Target Drugs in Pharmacology and Medicinal Chemistry
- Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial
- FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
- Evaluating dermatologists’ knowledge of and attitudes toward Janus kinase inhibitor therapy for the treatment of alopecia areata
- Health‐related quality of life and well‐being in pediatric patients with alopecia areata and their caregivers
- Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study
- Patient preferences in the treatment of alopecia areata: A review of the literature
- Short Snips: YouTube Shorts Recommendations for Hair Loss and Alopecia